People · Operator

CHRISTOPHER F. GARCIA

Named in public records as an officer, director or promoter · active 2013–2013 · Other Health Care

1
Companies
3
Filings
$56.4M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Remedy Partners, Inc.Other Health CareSeries B$56.4M$795.3M2013
Operator network

CHRISTOPHER F. GARCIA at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

W. Robert Dahl · 6 companies · 1 sharedW. Robert DahlEdward J Zecchini · 4 companies · 1 sharedEdward J ZecchiniSTEPHEN F. WIGGINS · 2 companies · 1 sharedSTEPHEN F. WIGGINSCHARLES A. WIGGINS · 1 companies · 1 sharedCHARLES A. WIGGINSGEORGE W. CARMANY, III · 1 companies · 1 sharedGEORGE W. CARMANY…JOSEPH A. O'CONNOR · 1 companies · 1 sharedJOSEPH A. O'CONNORJOSEPH F. O'CONNOR · 1 companies · 1 sharedJOSEPH F. O'CONNORMICHAEL W. STAMM · 1 companies · 1 sharedMICHAEL W. STAMMRICHARD F. GOODMAN · 1 companies · 1 sharedRICHARD F. GOODMANROBERT C. MEIER · 1 companies · 1 sharedROBERT C. MEIERTHOMAS W. O'DONNELL III · 1 companies · 1 sharedTHOMAS W. O'DONNE…WILLIAM F. BORNE · 1 companies · 1 sharedWILLIAM F. BORNERemedy Partners, Inc. · $56.4M raisedRemedy Partners, Inc.CHRISTOPHER F. GARCIACG
CHRISTOPHER F. GARCIA Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside CHRISTOPHER F. GARCIA on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
W. Robert Dahl16
Edward J Zecchini14
STEPHEN F. WIGGINS12
RICHARD F. GOODMAN11
WILLIAM F. BORNE11
GEORGE W. CARMANY, III11
THOMAS W. O'DONNELL III11
JOSEPH F. O'CONNOR11
ROBERT C. MEIER11
MICHAEL W. STAMM11
CHARLES A. WIGGINS11
JOSEPH A. O'CONNOR11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.